SEC Form 4Coverage since Aug 4, 2026
$FATE insider trading
Over the last 12 months, Fate Therapeutics insiders reported no purchases and 2 sales totaling $204K across SEC Form 4 filings.
- Bought · 12m
- — 0 events
- Sold · 12m
- $204K 2 events
- Events · 12m
- 2 Form 4 filings, grouped
- Insiders · 12m
- 2 distinct reporters
- 10b5-1 share
- 0% pre-arranged plans
Side
Price · $FATE · 12Mvia TradingView
Top insiders · 12m
TAHL CINDYSee Remarks1× · $95K
Valamehr BahramPresident and CEO1× · $108K
All insider trades
2 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | TAHL CINDYSee Remarks · O | ▼ Sale | 38,800 | $2.46 | $95K | -6.2% | — |
| Aug 4, 2026 | Valamehr BahramPresident and CEO · O·D | ▼ Sale | 43,947 | $2.46 | $108K | -6.9% | — |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $FATE feed.